neurology

News

FDA lets off Novartis after gene therapy data row

Novartis is off the hook following the FDA’s review of data manipulation in the filing of its hugely expensive spinal muscular atrophy gene therapy Zolgensma.

News

Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi

News

FDA approves 'potential blockbuster' migraine jab from Lundb...

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.

News

Teva draws blank in phase 3 Tourette Syndrome trial

Teva’s late stage trials of a potential drug for Tourette Syndrome have drawn a blank, just when the troubled pharma needs to freshen up its portfolio.

News

Warren Buffet shocks Wall Street with Biogen gamble

Biogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Buffet thinks the volatile stock is worth gambling on as the company prepa

FDA lets off Novartis after gene therapy data row

Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

FDA approves 'potential blockbuster' migraine jab from Lundb...

Teva draws blank in phase 3 Tourette Syndrome trial

Warren Buffet shocks Wall Street with Biogen gamble

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

neurology

Editor's Picks